Global Urinary Tract Infection Market Size is Projected to Reach USD 11.85 billion by 2031, Growing at a CAGR of 3.2%: Straits Research
12 févr. 2024 08h00 HE
|
Straits Research
New York, United States, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Urinary tract infections affect the kidneys, ureters, bladder, or urethra (UTI). The development of novel urinary incontinence devices, the...
Global Urinary Tract Infection Testing Market Projected to Generate a Revenue of $1,027.4 Million and Rise at a CAGR of 6.2% during the Analysis Period 2022-2031 [240-Pages] | Details by Research Dive
24 janv. 2023 09h03 HE
|
Research Dive
New York, USA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Research Dive has added a new report to its offering titled, “Urinary Tract Infection Testing Market by Infection Type (Urethritis, Cystitis,...
Outlook on the Urinary Tract Infection Testing Global Market to 2030 - Featuring Accelerate Diagnostics, Bio-Rad Laboratories and Danaher Among Others
30 août 2022 08h33 HE
|
Research and Markets
Dublin, Aug. 30, 2022 (GLOBE NEWSWIRE) -- The "Global Urinary Tract Infection Testing Market Size, Share & Trends Analysis by Type (Urethritis, Cystitis, Pyelonephritis), by End-Use (Reference...
Hematuria Treatment Market Size ($1,103.61Mn by 2028) Led by Urinary Tract Infections (17.31% Market Share in 2020) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
29 oct. 2021 13h45 HE
|
The Insight Partners
New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Hematuria Treatment Market: Key InsightsAccording to our new research study on Hematuria Treatment Market Size and Forecast to 2028 - COVID-19 Impact and...
Cempra to Present at Two Upcoming Investor Conferences
09 nov. 2016 07h30 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) as Solithromycin Progresses to Phase 3 Studies in Japan
01 nov. 2016 07h30 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports Third Quarter 2016 Financial Results and Provides Corporate Update
27 oct. 2016 16h15 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report Third Quarter 2016 Financial Results
25 oct. 2016 16h15 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Presents Analysis Showing Rates of Failure for Existing CABP Antibiotics From Claims Database at Academy of Managed Care Pharmacy Meeting
04 oct. 2016 16h15 HE
|
Cempra, Inc.
—More than 20 percent of adult CABP patients failed initial antibiotic monotherapy, including approximately one of four elderly patients— —Average U.S. macrolide resistance to S. pneumoniae...
Cempra Announces Anti-NASH Effects of Solithromycin: Interim Results From Phase 2 Study
29 sept. 2016 16h15 HE
|
Cempra, Inc.
— Pre/post treatment biopsies confirm mean NAS reduction of 1.3 points after 90 days of treatment with solithromycin — — All six patients showed ALT reductions after 90 days of treatment with...